NDTV-Dettol Banega Swasth Swachh India NDTV-Dettol Banega Swasth Swachh India
  • Home/
  • News/
  • Exposure To Common Cold Virus May Protect From COVID-19: Study

News

Exposure To Common Cold Virus May Protect From COVID-19: Study

The research, published in the Journal of Experimental Medicine, found that rhinovirus, the common respiratory virus, jump-starts activity of interferon-stimulated genes. These genes trigger early-response molecules in the immune system which can stop reproduction of SARS-CoV-2 that causes COVID

Exposure To Common Cold Virus May Protect From COVID-19: Study
Highlights
  • Researchers wanted to study the defence system early in course of COVID
  • For first 3 days, viral load in the tissue doubled about every 6hours
  • In some patients the virus grew even faster, the researchers found

Washington: Exposure to the virus that causes common cold can provide protection against infection by the SARS-CoV-2 virus behind COVID-19, according to a study. The research, published on Tuesday (June 15) in the Journal of Experimental Medicine, found that rhinovirus, the common respiratory virus, jump-starts the activity of interferon-stimulated genes. These genes trigger early-response molecules in the immune system which can stop reproduction of the SARS-CoV-2, the virus that causes COVID-19, within airway tissues infected with the cold, the researchers said.

Also Read: COVID-19 Vaccine Covishield: India Will Revisit Dosage Interval Based On Emerging Data

Triggering these defences early in the course of COVID-19 infection holds promise to prevent or treat the infection, said senior study author, Ellen Foxman, assistant professor at the Yale School of Medicine in the US.

One way to do this, Ms Foxman said, is by treating patients with interferons, an immune system protein which is also available as a drug.

But it all depends upon the timing, she said.

Previous work showed that at the later stages of COVID-19, high interferon levels are associated with worse disease outcomes, and may fuel overactive immune responses.

However, recent genetic studies show that interferon-stimulated genes can also be protective in cases of COVID-19 infection.

The researchers wanted to study this defence system early in the course of COVID-19 infection.

Also Read: 1-20 Age Group Accounted For Less Than 12 Per Cent Of COVID Cases In Both Waves: Government

They decided to study whether rhinoviruses would have beneficial impact against the SARS-CoV-2 virus.

The team infected lab-grown human airway tissue with the virus and found that for the first three days, viral load in the tissue doubled about every six hours.

However, the researchers found that reproduction of the COVID-19 virus was completely stopped in tissue which had been exposed to rhinovirus.

If antiviral defences were blocked, the SARS-CoV-2 could reproduce in airway tissue previously exposed to rhinovirus.

The same defences slowed down SARS-CoV-2 infection even without rhinovirus, but only if the infectious dose was low.

This suggests that the viral load at the time of exposure makes a difference in whether the body can effectively fight the infection, the researchers noted.

The team of researchers also studied nasal swab samples from patients diagnosed close to the start of infection.

They found evidence of rapid growth of SARS-CoV-2 in the first few days of infection, followed by activation of the body’s defences.

According to their findings, the virus typically increased rapidly for the first few days of infection, before host defences kicked in, doubling about every six hours as seen in the lab.

Also Read: Most Drugs For Treating Adult COVID Patients Not Recommended For Kids: Government Guidelines

In some patients the virus grew even faster, the researchers found.

There appears to be a viral sweet spot at the beginning of COVID-19, during which the virus replicates exponentially before it triggers a strong defence response, Ms Foxman said.

She explained that interferon treatment holds promise but it could be tricky, because it would be mostly effective in the days immediately after infection, when many people exhibit no symptoms.

In theory, interferon treatment could be used as a preventive in people at high risk who have been in close contact with others diagnosed with COVID-19, they said.

Trials of interferon in COVID-19 are underway, and so far show a possible benefit early in infection, but not when given later. These findings may help explain why at times of year when colds are common, rates of infections with other viruses such as influenza tend to be lower, Ms Foxman added.

Also Read: Preparing For Possible Third Wave Of COVID-19, Delhi Government To Train 5,000 Youths As Health Assistants

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

[corona_data_new]
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This website follows the DNPA Code of Ethics

© Copyright NDTV Convergence Limited 2024. All rights reserved.